Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686155 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL29401630 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL31689008 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL31000586 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL1000852 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL1336708 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL1334889 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL1335555 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL1000853 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A | |
| SCHEMBL30802568 | 1.00 | FABP5 (0.46) | FABP5FABP7POLBATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FABP5 478/4885FABP7 1342/4885POLB 1695/4885 |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | FABP5 540/4885FABP7 3140/4885POLB 3960/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FABP5 3388/4885FABP7 4395/4885POLB 6/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | FABP5 540/4885FABP7 3140/4885POLB 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.